



(51) International Patent Classification:

C07H 19/00 (2006.01) A61K 31/7072 (2006.01)
C07H 19/06 (2006.01) A61K 31/7076 (2006.01)
C07H 19/20 (2006.01) A61K 31/708 (2006.01)
C07H 19/16 (2006.01) A61P 31/04 (2006.01)
A61K 31/7068 (2006.01)

(21) International Application Number:

PCT/US2013/063731

(22) International Filing Date:

7 October 2013 (07.10.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/711,131 8 October 2012 (08.10.2012) US
61/807,249 1 April 2013 (01.04.2013) US

(71) Applicants: IDENIX PHARMACEUTICALS, INC. [US/US]; 320 Bent Street, Floor 4, Cambridge, Massachusetts 02141 (US). CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE; 3 Rue Michel-Ange, F-75794 Paris Cedex 16 (FR). UNIVERSITÉ MONTPELLIER 2 SCIENCES ET TECHNIQUES; 2 Place Eugène Bataillon, F-34095 Montpellier Cedex 5 (FR).

(72) Inventors: GOSSELIN, Gilles; 487 Rue Celleneuve St. Hilaire, F-34070 Montpellier (FR). PARSY, Christophe Claude; 6 Rue des Cedres, F-34830 Jacou (FR). ALEX-ANDRE, Francois-Rene; 6 rue d'Auvergne, F-34090 Montpellier (FR). RAHALI, Houcine; 331 Traverse des Genêts, F-30126 Saint Laurent des Arbres (FR). GRIF-FON, Jean-François; 4 Rue des Lilas, F-34280 Teyran (FR). MILHAU, Julien; 83 bis, chemin des Courrialès, F-34800 Canet (FR). SURLERAUX, Dominique; Rue de La Scaillee 13, B-1440 Wauthier-Braine (BE). DOUSSON, Cyril B.; 15 Lot La Source 1, F-34800 Canet (FR). PIERRA, Claire; Lot Pioch Ourbatieu, 6 Rue Ernestine

Montreuil, F-34570 Montarnaud (FR). MOUSSA, Adel M.; 34 Newbridge Avenue, Burlington, Massachusetts 01803 (US). MAYES, Benjamin Alexander; 65 Franconia Street, Boston, Massachusetts 02122 (US).

(74) Agents: PATHAK, Rahul et al.; Squire Sanders (US) LLP, 275 Battery Street, Suite 2600, San Francisco, California 94111 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

[Continued on next page]

(54) Title: 2'-CHLORO NUCLEOSIDE ANALOGS FOR HCV INFECTION



(2001)

(57) Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2'-chloro nucleosides according to Formula 2001: (2001); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein B, Z and PD are as described herein.

Published:

— *with international search report (Art. 21(3))*

— *with amended claims (Art. 19(1))*